M-A: Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus.

Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials – BMC Endocrine Disorders

Commentary on Twitter

New meta-analysis

GLP-1 receptor agonists ⬇️risk of death from cardiovascular causes & fatal or non-fatal stroke compared with the placebo in T2 diabeteshttps://t.co/278nvlBF5e@drpatrickholmes pic.twitter.com/F8sl5kLq2s

— Prof Kamlesh Khunti (@kamleshkhunti) May 17, 2022

Under a http://creativecommons.org/licenses/by/4.0/ license